Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.57 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371176 | 0.98 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL127882 | 0.98 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL476479 | 0.96 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29421834 | 0.96 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL957295 | 0.96 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Cysteamine SCHEMBL2637878 | 0.90 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL1271908 | 0.87 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL10802711 | 0.87 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL11833495 | 0.86 | EHMT2 (0.70) | EHMT2EHMT1APOBEC3GALDH1A1MAPT | |
| SCHEMBL3991936 | 0.86 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9550787-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-3100745-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | Immunogen, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9265841-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150030616-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8809320-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8802667-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2393362-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | Immunogen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | EHMT2 3304/4885EHMT1 3158/4885APOBEC3G 1671/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20150030616-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | EHMT2 3304/4885EHMT1 3158/4885APOBEC3G 1671/4885 |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | EHMT2 3794/4885EHMT1 3670/4885APOBEC3G 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.